228 citations
,
February 2003 in “Urology” This article discusses the side effects of androgen deprivation therapy for nonmetastatic prostate cancer, highlighting the need for clinical trials to systematically study these effects.
45 citations
,
April 2021 in “Current Treatment Options in Oncology” This review discusses cardiovascular risks associated with androgen deprivation therapy in prostate cancer patients and highlights ongoing research, including the potential reduced COVID-19 susceptibility, but reports no new results.
38 citations
,
August 2003 in “International Journal of Urology” In this study, androgen deprivation, particularly through finasteride treatment, effectively reduced chronic bacterial prostatitis severity in rats, suggesting potential for improved treatment modalities combining finasteride and levofloxacin.
35 citations
,
January 2012 in “The Journal of Sexual Medicine” This review examines various androgen deprivation therapy methods for advanced prostate cancer, highlighting benefits and potential cardiovascular and sexual adverse effects, but reports no new clinical results.
12 citations
,
August 2020 in “Annals of Oncology” This study found that androgen deprivation therapy in prostate cancer patients was associated with fewer SARS-CoV-2 infections but did not reduce COVID-19 disease severity or hospitalizations.